Research graph
References from The Potential of Bacteriophage-Antibiotic Combination Therapy in Treating Infections with Multidrug-Resistant Bacteria. Local targets link to admitted publications; unresolved targets remain external evidence.
Multidrug-Resistant Bacteria in Hospital Wastewater of the Korle Bu Teaching Hospital in Accra, Ghana
2022 · External reference
10.1371/journal.pone.0279715
10.1371/journal.pone.0279715 · External reference
Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis
10.1016/s0140-6736(21)02724-0 · 2022 · External reference
10.3390/antibiotics12020255
10.3390/antibiotics12020255 · External reference
Methicillin-Resistant Staphylococcus aureus in the oral cavity: Implications for antibiotic prophylaxis and surveillance
2020 · External reference
10.1371/journal.pone.0283706
10.1371/journal.pone.0283706 · External reference
In vitro antimicrobial activity of crude propolis extracts and fractions
10.1093/femsmc/xtad010 · 2023 · External reference
Evaluation of separation and purification processes in the antibiotic industry
10.1007/bf02930830 · 1988 · External reference
Coprophilous fungi: Antibiotic discovery and functions in an underexplored arena of microbial defensive mutualism
10.1016/j.mib.2013.08.001 · 2013 · External reference
Exploitation of fungal biodiversity for discovery of novel antibiotics
10.1007/82_2016_496 · 2016 · External reference
Bacterial viruses against viruses pathogenic for man?
10.1016/j.virusres.2005.01.009 · 2005 · External reference
Unexploited opportunities for phage therapy
10.3389/fphar.2015.00180 · 2015 · External reference
Current challenges and future opportunities of phage therapy
10.1093/femsre/fuaa017 · 2020 · External reference
The pan-immune system of bacteria: Antiviral defense as a community resource
10.1038/s41579-019-0278-2 · 2020 · External reference
10.1007/978-3-030-26736-0
10.1007/978-3-030-26736-0 · External reference
10.3390/v10070351
10.3390/v10070351 · External reference
Bacteriophage resistance mechanisms
10.1038/nrmicro2315 · 2010 · External reference
Antibiotics: Past, present and future
10.1016/j.mib.2019.10.008 · 2019 · External reference
10.3390/antibiotics8020045
10.3390/antibiotics8020045 · External reference
Do we really understand how antibiotics work?
2020 · External reference
Penicillin-resistant pneumococcus and risk of treatment failure in pneumonia
10.1136/adc.2006.111625 · 2008 · External reference
Clinical characteristics of pneumococcal bacteremia in adults: The effect of penicillin resistance on the mortality of patients with pneumococcal bacteremia
10.4046/trd.1999.47.2.184 · 1999 · External reference
Focus: Drug development: Penicillin’s discovery and antibiotic resistance: Lessons for the future?
2017 · External reference
Antibiotic resistance profiling and phenotyping of Aeromonas species isolated from aquatic sources
10.1016/j.sjbs.2015.09.016 · 2017 · External reference
The antibiotic resistance crisis: Part 1: Causes and threats
2015 · External reference
10.3390/pathogens11121517
10.3390/pathogens11121517 · External reference
Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe
10.2807/ese.13.47.19045-en · 2008 · External reference
Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections
10.1128/cmr.00031-19 · 2019 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Antimicrobial stewardship: Fighting antimicrobial resistance and protecting global public health
10.2147/idr.s290835 · 2020 · External reference
Unresolved reference
External reference
Phage therapy of pulmonary infections
10.1080/21597081.2015.1020260 · 2015 · External reference
Early clinical experience of bacteriophage therapy in 3 lung transplant recipients
10.1111/ajt.15503 · 2019 · External reference
Phage therapy for respiratory infections
10.1016/j.addr.2018.08.001 · 2018 · External reference
Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: A case report
10.1016/j.resmic.2018.05.001 · 2018 · External reference
10.1007/978-3-030-03077-3
10.1007/978-3-030-03077-3 · External reference
Bacteriophage therapy of chronic nonhealing wound: Clinical study
10.1177/1534734619835115 · 2019 · External reference
13 Phage Therapy of Wounds and Related Purulent Infections
2012 · External reference
10.3390/antibiotics8040182
10.3390/antibiotics8040182 · External reference
10.1128/microbiolspec.bad-0003-2016
10.1128/microbiolspec.bad-0003-2016 · External reference
Phage treatment of human infections
10.4161/bact.1.2.15845 · 2011 · External reference
Bacteriophage Sb-1 enhances antibiotic activity against biofilm, degrades exopolysaccharide matrix and targets persisters of Staphylococcus aureus
10.1016/j.ijantimicag.2018.09.006 · 2018 · External reference
Staphylococcus aureus Bacteriophage Suppresses LPS-Induced Inflammation in MAC-T Bovine Mammary Epithelial Cells
10.3389/fmicb.2018.01614 · 2018 · External reference
10.1371/journal.pone.0168615
10.1371/journal.pone.0168615 · External reference
P. aeruginosa flow-cell biofilms are enhanced by repeated phage treatments but can be eradicated by phage–ciprofloxacin combination: —Monitoring the phage–P. aeruginosa biofilms interactions
10.1093/femspd/ftz011 · 2019 · External reference
Antimicrobial assessment of phage therapy using a porcine model of biofilm infection
10.1016/j.ijpharm.2018.12.004 · 2019 · External reference
Isolation and characterization of a bacteriophage and its potential to disrupt multi-drug resistant Pseudomonas aeruginosa biofilms
10.1016/j.micpath.2019.01.032 · 2019 · External reference
10.3390/v15020499
10.3390/v15020499 · External reference
Phage-antibiotic synergy is driven by a unique combination of antibacterial mechanism of action and stoichiometry
10.1128/mbio.01462-20 · 2020 · External reference
A combination therapy of Phages and Antibiotics: Two is better than one
10.7150/ijbs.60551 · 2021 · External reference
10.3390/antibiotics12020417
10.3390/antibiotics12020417 · External reference
Bacteriophages and antibiotic interactions in clinical practice: What we have learned so far
10.1186/s12929-022-00806-1 · 2022 · External reference
Bacteriophages: A Therapy Concept against Multi-Drug–Resistant Bacteria
10.1089/sur.2018.184 · 2018 · External reference
10.3390/ph16050744
10.3390/ph16050744 · External reference
Phage Therapy for Antibiotic-Resistant Bacterial Infections
10.1146/annurev-med-080219-122208 · 2022 · External reference
Assessment of phage-mediated inhibition of Salmonella typhimurium treated with sublethal concentrations of ceftriaxone and ciprofloxacin
10.1093/femsle/fnaa159 · 2020 · External reference
Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?
10.1016/j.clinthera.2020.07.014 · 2020 · External reference
Combined Bacteriophage and Antibiotic Treatment Prevents Pseudomonas aeruginosa Infection of Wild Type and cftr-Epithelial Cells
10.3389/fmicb.2020.01947 · 2020 · External reference
Bacteriophage therapy against Pseudomonas aeruginosa biofilms: A review
10.1186/s12941-020-00389-5 · 2020 · External reference
10.3390/antibiotics8030103
10.3390/antibiotics8030103 · External reference
10.1371/journal.pone.0106628
10.1371/journal.pone.0106628 · External reference
Evolutionary Rationale for Phages as Complements of Antibiotics
10.1016/j.tim.2015.12.011 · 2016 · External reference
The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa
10.1007/s10096-021-04308-0 · 2021 · External reference
Bacteriophage-encoded depolymerases: Their diversity and biotechnological applications
10.1007/s00253-015-7247-0 · 2016 · External reference
10.1371/journal.pone.0000799
10.1371/journal.pone.0000799 · External reference
Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection
10.1128/aac.00954-17 · 2017 · External reference
Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa
10.1038/srep26717 · 2016 · External reference
Burkholderia cepacia Complex Phage-Antibiotic Synergy (PAS): Antibiotics Stimulate Lytic Phage Activity
10.1128/aem.02850-14 · 2015 · External reference
Piperacillin and ceftazidime produce the strongest synergistic phage–antibiotic effect in Pseudomonas aeruginosa
10.1007/s00705-018-3811-0 · 2018 · External reference
Bacteriophages as Adjuvant to Antibiotics for the Treatment of Periprosthetic Joint Infection Caused by Multidrug-Resistant Pseudomonas aeruginosa
10.1128/aac.00924-19 · 2019 · External reference
Effect of Bacteriophage Infection in Combination with Tobramycin on the Emergence of Resistance in Escherichia coli and Pseudomonas aeruginosa Biofilms
10.3390/v6103778 · 2014 · External reference
Phage therapy as an alternative or complementary strategy to prevent and control biofilm-related infections
10.1016/j.mib.2017.09.004 · 2017 · External reference
Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy
10.1073/pnas.0800442106 · 2009 · External reference
Characterization of induced Staphylococcus aureus bacteriophage SAP-26 and its anti-biofilm activity with rifampicin
10.1080/08927014.2011.631169 · 2011 · External reference
10.1371/journal.pone.0051017
10.1371/journal.pone.0051017 · External reference
Enhanced antibacterial effect of the novel T4-like bacteriophage KARL-1 in combination with antibiotics against multi-drug resistant Acinetobacter baumannii
10.1038/s41598-018-32344-y · 2018 · External reference
Global Challenge of Multidrug-Resistant Acinetobacter baumannii
10.1128/aac.01464-06 · 2007 · External reference
Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy
10.3389/fcimb.2019.00022 · 2019 · External reference
Chapter 3—Clinical Aspects of Phage Therapy
10.1016/b978-0-12-394438-2.00003-7 · 2012 · External reference
Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection
10.1099/jmm.0.029744-0 · 2011 · External reference
Bacteriophage Therapeutics: A Primer for Clinicians on Phage-Antibiotic Combinations
10.1002/phar.2358 · 2020 · External reference
Phage treatment of an aortic graft infected with Pseudomonas aeruginosa
10.1093/emph/eoy005 · 2018 · External reference
Antibiotics in agriculture and the risk to human health: How worried should we be?
10.1111/eva.12185 · 2014 · External reference
Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria
10.1016/j.chom.2019.01.014 · 2019 · External reference
Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms: Phages limit bacterial antibiotic resistance
10.1111/j.1752-4571.2011.00236.x · 2012 · External reference
Coverage of diarrhea-associated Escherichia coli isolates from different origins with two types of phage cocktails
10.1111/1751-7915.12113 · 2014 · External reference
PhageScore: A simple method for comparative evaluation of bacteriophages lytic activity
10.1016/j.bej.2020.107652 · 2020 · External reference
10.1371/journal.pone.0004944
10.1371/journal.pone.0004944 · External reference
Rapid and quantitative automated measurement of bacteriophage activity against cystic fibrosis isolates of Pseudomonas aeruginosa
10.1111/j.1365-2672.2010.04928.x · 2011 · External reference
PhageScore-based analysis of Acinetobacter baumannii infecting phages antibiotic interaction in liquid medium
10.1007/s00203-022-03020-7 · 2022 · External reference
Bacteriophages adhering to mucus provide a non-host-derived immunity
10.1073/pnas.1305923110 · 2013 · External reference
Engineered bacteriophage therapeutics: Rationale, challenges and future
10.1007/s40259-021-00480-z · 2021 · External reference
Engineering phage host-range and suppressing bacterial resistance through phage tail fiber mutagenesis
10.1016/j.cell.2019.09.015 · 2019 · External reference
Genetic engineering of bacteriophages against infectious diseases
10.3389/fmicb.2019.00954 · 2019 · External reference
Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus
10.1038/s41591-019-0437-z · 2019 · External reference
10.1371/journal.pone.0220421
10.1371/journal.pone.0220421 · External reference
JD419, a Staphylococcus aureus phage with a unique morphology and broad host range
10.3389/fmicb.2021.602902 · 2021 · External reference
Lytic and genomic properties of spontaneous host-range Kayvirus mutants prove their suitability for upgrading phage therapeutics against Staphylococci
10.1038/s41598-019-41868-w · 2019 · External reference
CRISPR Immunity Drives Rapid Phage Genome Evolution in Streptococcus thermophilus
10.1128/mbio.00262-15 · 2015 · External reference
10.3390/v15051210
10.3390/v15051210 · External reference
Phage therapy in the postantibiotic era
10.1128/cmr.00066-18 · 2019 · External reference
10.3390/v10020064
10.3390/v10020064 · External reference
Bacteriophage delivering hydrogels reduce biofilm formation in vitro and infection in vivo
10.1002/jbm.a.36790 · 2020 · External reference
Combined treatment of Pseudomonas aeruginosa biofilms with bacteriophages and chlorine
10.1002/bit.24630 · 2013 · External reference
Chestnut Honey and Bacteriophage Application to Control Pseudomonas aeruginosa and Escherichia coli Biofilms: Evaluation in an ex vivo Wound Model
10.3389/fmicb.2018.01725 · 2018 · External reference
Bacteriophages ϕMR299-2 and ϕNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells
10.1128/mbio.00029-12 · 2012 · External reference
Phage as a modulator of immune responses: Practical implications for phage therapy
10.1016/b978-0-12-394438-2.00002-5 · 2012 · External reference
Effects of Sequential and Simultaneous Applications of Bacteriophages on Populations of Pseudomonas aeruginosa In Vitro and in Wax Moth Larvae
10.1128/aem.00757-12 · 2012 · External reference
The next generation of bacteriophage therapy
10.1016/j.mib.2011.07.028 · 2011 · External reference
Achieving global targets for antimicrobial resistance
10.1126/science.aaf9286 · 2016 · External reference
The influence of external factors on bacteriophages—Review
10.1007/s12223-011-0039-8 · 2011 · External reference
Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation—A proof-of-principle study in a P. aeruginosa lung infection model
10.1016/j.ejpb.2020.11.019 · 2021 · External reference
Advancing bacteriophages as a treatment of antibiotic-resistant bacterial pulmonary infections
10.1097/mcp.0000000000000864 · 2022 · External reference
10.3390/ani13081328
10.3390/ani13081328 · External reference
Treatment of in vitro enterohemorrhagic Escherichia coli infection using phage and probiotics
10.1111/jam.13124 · 2016 · External reference
Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh
10.1016/j.virol.2012.09.002 · 2012 · External reference
Bacteriophages: A weapon against mixed-species biofilms in the food processing environment
10.1111/jam.15421 · 2022 · External reference
Bacteriophage–Ciprofloxacin Combination Effectiveness Depends on Staphylococcus aureus–Candida albicans Dual-Species Communities’ Growth Model
10.1089/mdr.2021.0324 · 2022 · External reference
Environmental Phage-Based Cocktail and Antibiotic Combination Effects on Acinetobacter baumannii Biofilm in a Human Urine Model
10.1089/mdr.2020.0083 · 2021 · External reference
10.3390/ijms21124390
10.3390/ijms21124390 · External reference
Bacteriophage-based synthetic biology for the study of infectious diseases
10.1016/j.mib.2014.05.022 · 2014 · External reference
10.3390/v11040352
10.3390/v11040352 · External reference
Bacteriophage treatment of intransigent diabetic toe ulcers: A case series
10.12968/jowc.2016.25.7.s27 · 2016 · External reference
10.1371/journal.pone.0031698
10.1371/journal.pone.0031698 · External reference
10.1371/journal.pone.0124280
10.1371/journal.pone.0124280 · External reference
Phage lytic proteins: Biotechnological applications beyond clinical antimicrobials
2016 · External reference
Phage cocktails and the future of phage therapy
10.2217/fmb.13.47 · 2013 · External reference
Biofilm susceptibility to bacteriophage attack: The role of phage-borne polysaccharide depolymerase
10.1099/00221287-144-11-3039 · 1998 · External reference
Phage Therapy in Clinical Practice: Treatment of Human Infections
10.2174/138920110790725401 · 2010 · External reference
Bacteriophage therapy: A regulatory perspective
10.1093/jac/dkw083 · 2016 · External reference
